Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus

Abstract NL63 is an alphacoronavirus that uses the same ACE2 receptor as SARS-CoV and SARS-CoV-2, but generally causes mild respiratory illness. In a cohort of healthy adults, we characterised humoral responses against NL63 spike and isolated a panel of human monoclonal antibodies (mAbs), including...

Full description

Saved in:
Bibliographic Details
Main Authors: Wen Shi Lee, George Taiaroa, Robyn Esterbauer, Meghan Conlan, Jessica A. Neil, Matthew J. Gartner, Monique Smith, Mingyang Wang, Rory A. Shepherd, Thomas Tran, Phillip Pymm, Lara S. U. Schwab, Andrew Kelly, Ellie Reilly, Thakshila Amarasena, Bruce D. Wines, P. Mark Hogarth, Jennifer A. Juno, Stephen J. Kent, Hyon-Xhi Tan, Kanta Subbarao, Adam K. Wheatley
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:npj Viruses
Online Access:https://doi.org/10.1038/s44298-025-00116-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849712950353330176
author Wen Shi Lee
George Taiaroa
Robyn Esterbauer
Meghan Conlan
Jessica A. Neil
Matthew J. Gartner
Monique Smith
Mingyang Wang
Rory A. Shepherd
Thomas Tran
Phillip Pymm
Lara S. U. Schwab
Andrew Kelly
Ellie Reilly
Thakshila Amarasena
Bruce D. Wines
P. Mark Hogarth
Jennifer A. Juno
Stephen J. Kent
Hyon-Xhi Tan
Kanta Subbarao
Adam K. Wheatley
author_facet Wen Shi Lee
George Taiaroa
Robyn Esterbauer
Meghan Conlan
Jessica A. Neil
Matthew J. Gartner
Monique Smith
Mingyang Wang
Rory A. Shepherd
Thomas Tran
Phillip Pymm
Lara S. U. Schwab
Andrew Kelly
Ellie Reilly
Thakshila Amarasena
Bruce D. Wines
P. Mark Hogarth
Jennifer A. Juno
Stephen J. Kent
Hyon-Xhi Tan
Kanta Subbarao
Adam K. Wheatley
author_sort Wen Shi Lee
collection DOAJ
description Abstract NL63 is an alphacoronavirus that uses the same ACE2 receptor as SARS-CoV and SARS-CoV-2, but generally causes mild respiratory illness. In a cohort of healthy adults, we characterised humoral responses against NL63 spike and isolated a panel of human monoclonal antibodies (mAbs), including five with potent viral neutralising activity. Four neutralising mAbs blocked ACE2 receptor engagement and were found to target the receptor binding motif. A single mAb targeting the S2 subunit displayed potent neutralisation activity comparable to those directly blocking receptor engagement. The S2 mAb targets a membrane proximal heptad repeat 2 (HR2) region in spike that is absent in betacoronaviruses, potentially revealing a site of vulnerability unique to alphacoronaviruses. For all neutralising mAbs, putative epitopes were highly conserved in over 200 NL63 sequences, including recent clinical isolates. A deeper understanding of the recognition of alphacoronavirus spike by human antibodies will guide vaccine and therapeutic development against alphacoronavirus threats.
format Article
id doaj-art-3b0cfe57128e47a6a2fb24656b7aadaf
institution DOAJ
issn 2948-1767
language English
publishDate 2025-04-01
publisher Nature Portfolio
record_format Article
series npj Viruses
spelling doaj-art-3b0cfe57128e47a6a2fb24656b7aadaf2025-08-20T03:14:07ZengNature Portfolionpj Viruses2948-17672025-04-013111010.1038/s44298-025-00116-xPotent neutralising monoclonal antibodies targeting the spike of NL63 coronavirusWen Shi Lee0George Taiaroa1Robyn Esterbauer2Meghan Conlan3Jessica A. Neil4Matthew J. Gartner5Monique Smith6Mingyang Wang7Rory A. Shepherd8Thomas Tran9Phillip Pymm10Lara S. U. Schwab11Andrew Kelly12Ellie Reilly13Thakshila Amarasena14Bruce D. Wines15P. Mark Hogarth16Jennifer A. Juno17Stephen J. Kent18Hyon-Xhi Tan19Kanta Subbarao20Adam K. Wheatley21Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneVictorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and ImmunityDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of MelbourneVictorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and ImmunityDivision of Infection and Global Health, Walter and Eliza Hall InstituteDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneBurnet InstituteBurnet InstituteDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of MelbourneAbstract NL63 is an alphacoronavirus that uses the same ACE2 receptor as SARS-CoV and SARS-CoV-2, but generally causes mild respiratory illness. In a cohort of healthy adults, we characterised humoral responses against NL63 spike and isolated a panel of human monoclonal antibodies (mAbs), including five with potent viral neutralising activity. Four neutralising mAbs blocked ACE2 receptor engagement and were found to target the receptor binding motif. A single mAb targeting the S2 subunit displayed potent neutralisation activity comparable to those directly blocking receptor engagement. The S2 mAb targets a membrane proximal heptad repeat 2 (HR2) region in spike that is absent in betacoronaviruses, potentially revealing a site of vulnerability unique to alphacoronaviruses. For all neutralising mAbs, putative epitopes were highly conserved in over 200 NL63 sequences, including recent clinical isolates. A deeper understanding of the recognition of alphacoronavirus spike by human antibodies will guide vaccine and therapeutic development against alphacoronavirus threats.https://doi.org/10.1038/s44298-025-00116-x
spellingShingle Wen Shi Lee
George Taiaroa
Robyn Esterbauer
Meghan Conlan
Jessica A. Neil
Matthew J. Gartner
Monique Smith
Mingyang Wang
Rory A. Shepherd
Thomas Tran
Phillip Pymm
Lara S. U. Schwab
Andrew Kelly
Ellie Reilly
Thakshila Amarasena
Bruce D. Wines
P. Mark Hogarth
Jennifer A. Juno
Stephen J. Kent
Hyon-Xhi Tan
Kanta Subbarao
Adam K. Wheatley
Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus
npj Viruses
title Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus
title_full Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus
title_fullStr Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus
title_full_unstemmed Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus
title_short Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus
title_sort potent neutralising monoclonal antibodies targeting the spike of nl63 coronavirus
url https://doi.org/10.1038/s44298-025-00116-x
work_keys_str_mv AT wenshilee potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT georgetaiaroa potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT robynesterbauer potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT meghanconlan potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT jessicaaneil potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT matthewjgartner potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT moniquesmith potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT mingyangwang potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT roryashepherd potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT thomastran potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT phillippymm potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT larasuschwab potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT andrewkelly potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT elliereilly potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT thakshilaamarasena potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT brucedwines potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT pmarkhogarth potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT jenniferajuno potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT stephenjkent potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT hyonxhitan potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT kantasubbarao potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus
AT adamkwheatley potentneutralisingmonoclonalantibodiestargetingthespikeofnl63coronavirus